Home > Insider Trading > Filing (0001209191-18-002591)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567514	Intra-Cellular Therapies Inc.	ITCI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291959	E Robert Davis	C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016	Svp, Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-01-03	2,648	$0.00	30,512	No	4	M	Direct
Common Stock	Disposition	2018-01-04	1,115	$15.60	29,397	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2018-01-03	2,648	$0.00	2,648	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2018-01-03	65,164	$0.00	65,164	$15.47
Common Stock	Restricted Stock Units	Acquisiton	2018-01-03	48,480	$0.00	48,480	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,298		No	4	M	Direct
65,164	2028-01-03	No	4	A	Direct
48,480		No	4	A	Direct

Footnotes

Restricted stock units convert into common stock on a one-for-one basis.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.